Skip to main content

Table 3 Effect of avelumab on classic and PD-L1+ classic immune cell subsets

From: Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

 

Pre vs 1 cycle

Pre vs 9 cycles

Subset

Increase

Minimal change

Decrease

P-value

Increase

Minimal change

Decrease

P-value

A. Classic subsets

 CD4

0 (0%)

18 (95%)

1 (5%)

0.0230 (↑^, 0.2070)

0 (0%)

12 (75%)

4 (25%)

0.0063 (↓^, 0.0567)

 CD8

1 (5%)

16 (84%)

2 (11%)

0.1447 (=)

3 (19%)

11 (68%)

2 (13%)

0.9799 (=)

 Tregs

7 (37%)

10 (53%)

2 (10%)

0.2253 (=)

2 (12%)

7 (44%)

7 (44%)

0.0934 (=)

 NK

5 (26%)

10 (53%)

4 (21%)

0.8288 (=)

0 (0%)

9 (56%)

7 (44%)

0.0182 (↓^, 0.1456)

 NK-T

2 (11%)

15 (78%)

2 (11%)

0.2413 (=)

1 (6%)

12 (75%)

3 (19%)

0.1046 (=)

 B cells

5 (26%)

12 (63%)

2 (11%)

0.7381 (=)

6 (38%)

5 (31%)

5 (31%)

0.8209 (=)

 cDC

3 (16%)

15 (79%)

1 (5%)

0.3955 (=)

6 (37%)

7 (44%)

3 (19%)

0.7436 (=)

 pDC

6 (32%)

8 (42%)

5 (26%)

0.4900 (=)

6 (38%)

9 (56%)

1 (6%)

0.0833 (=)

 MDSC

8 (42%)

8 (42%)

3 (16%)

0.1232 (=)

8 (50%)

7 (44%)

1 (6%)

0.0833 (=)

B. PD-L1+ classic subsets

 PD-L1+ CD4

5 (26%)

9 (48%)

5 (26%)

0.9843 (=)

3 (19%)

9 (56%)

4 (25%)

0.9999 (=)

 PD-L1+ CD8

4 (21%)

9 (47%)

6 (32%)

0.1688 (=)

4 (25%)

9 (56%)

3 (19%)

0.9999 (=)

 PD-L1+ Treg

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

 PD-L1+ NK

5 (26%)

6 (32%)

8 (42%)

0.4180 (=)

7 (44%)

7 (44%)

2 (12%)

0.1046 (=)

 PD-L1+ NK-T

5 (26%)

8 (42%)

6 (32%)

0.4900 (=)

6 (38%)

6 (38%)

4 (24%)

0.1439 (=)

 PD-L1+ B cells

9 (47%)

6 (32%)

4 (21%)

0.6507 (=)

6 (37%)

7 (44%)

3 (19%)

0.5282 (=)

 PD-L1+cDC

5 (26%)

8 (42%)

6 (32%)

0.3736 (=)

2 (13%)

4 (25%)

10 (62%)

0.0386 (↓*, 0.0772)

 PD-L1+ pDC

3 (16%)

2 (10%)

14 (74%)

0.0258 (↓*, 0.0774)

10 (63%)

1 (6%)

5 (31%)

0.0443 (↑, 0.1005)

 PD-L1+ MDSC

8 (42%)

6 (32%)

5 (26%)

0.6507 (=)

10 (63%)

4 (25%)

2 (12%)

0.0131 (↑, 0.1703)

  1. Classic subsets (A) and PD-L1+ classic subsets (B) were examined pre-therapy and post-1 cycle (n = 19) and 9 cycles (n = 16) of avelumab. Results are displayed as the number of patients (percentage of total patients) with an increase of more than 25%, minimal change of less than 25%, and a decrease of more than 25% compared to pre-therapy. Unadjusted p-values (= indicates no change; arrows indicate direction of change compared to pre-therapy; and Holm adjusted p-value is listed for subsets with significant unadjusted p-value) were calculated using the Wilcoxon matched-pairs signed rank test. n/a = not applicable as frequency of subset <0.01% PBMC; ^ = majority of patients with minimal change; * = difference in medians pre- vs post-therapy < 0.01
  2. cDC conventional dendritic cells, MDSC myeloid derived suppressor cell, NK natural killer, pDC plasmacytoid DC, PBMC peripheral blood mononuclear cell, Tregs regulatory T cells
Back to article page